BJERKHOLT ERIC 4

What Happened
Eric Bjerkholt, Chief Financial Officer of Mirum Pharmaceuticals (MIRM), had restricted stock units convert to common stock on Jan 21, 2026 and then sold a portion of those shares. A total of 3,334 shares converted/vested on Jan 21 (reported as an exercise/conversion of a derivative). Of those, 3,334 shares were recorded as disposed at $0.00 (tax withholding). On Jan 22, 2026 he sold 1,421 shares in an open-market transaction at $93.33 per share, generating $132,615 in proceeds. These actions are routine following RSU vesting rather than a cash purchase of shares.

Key Details

• Transaction dates and prices:
  • 2026-01-21: Conversion/vesting of 3,334 restricted stock units into common shares (reported as an exercise/conversion of a derivative).
  • 2026-01-21: 3,334 shares disposed at $0.00 (shares withheld for tax obligations).
  • 2026-01-22: Open-market sale of 1,421 shares at $93.33 each; proceeds $132,615.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Notable footnotes:
  • F1: Each RSU equals a contingent right to one share (or cash equivalent).
  • F2: Filing notes inclusion of 269 shares acquired under the Employee Stock Purchase Plan (Nov 10, 2025).
  • F3: Some shares were sold/withheld to satisfy tax withholding associated with RSU vesting.
  • F4: RSUs vest 1/3 each year on the anniversary of Jan 21, 2025; the 3,334 shares reflect a one‑third vesting tranche.
• Timeliness: Form filed Jan 23, 2026 for transactions on Jan 21–22, 2026 — appears timely (within the Form 4 filing window).

Context
This was primarily a conversion/vesting of RSUs followed by tax-related withholding and a subsequent open-market sale. Such sales after RSU vesting are common and typically reflect tax withholding and/or liquidity needs rather than an independent bullish or bearish signal about the company. The filing does not indicate any new cash purchases by the insider.